Jardiance Cost in Virginia 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Cost in Virginia Without Insurance?

Without insurance, Virginia residents face a retail cash price of approximately $680 per month for brand-name Jardiance in 2026. That figure reflects the Boehringer Ingelheim and Eli Lilly manufacturer list price, which has held near that level since the drug's approval. No generic empagliflozin has received FDA approval as of mid-2025, so there is no cheaper brand-equivalent tablet at retail.

GoodRx and similar discount aggregators can reduce the cash price at some Virginia pharmacies to a range of $560 to $630 per month, depending on the specific ZIP code and chain. CVS Health, Walgreens, and Walmart pharmacies in Northern Virginia and the Hampton Roads metro area tend to show the lowest GoodRx-negotiated prices, though these still represent a significant annual expense of $6,720 to $8,160.

The FDA-approved label for Jardiance confirms the 10 mg and 25 mg tablet formulations as the only commercially available strengths. [1] Patients asking for a "generic Jardiance" at a Virginia pharmacy will not find one on shelves today.

For patients whose adjusted gross income qualifies them, Boehringer Ingelheim's patient assistance program (myAbbVie Assist equivalent: the Lilly Cares Foundation and BI's "Jardiance for Patient Access" program) can provide the medication at no cost. Virginia residents with annual household incomes at or below 400% of the federal poverty level may apply directly through the manufacturer.

Virginia Medicaid Coverage for Jardiance

Virginia Medicaid covers Jardiance with prior authorization for three indications: type 2 diabetes mellitus, heart failure, and chronic kidney disease. Patients and prescribers must submit documentation confirming the diagnosis, an HbA1c value (for the diabetes indication), and evidence that first-line agents such as metformin have been tried or are contraindicated.

The Virginia Department of Medical Assistance Services (DMAS) places empagliflozin on the Preferred Drug List under the SGLT2 inhibitor class alongside dapagliflozin (Farxiga) and canagliflozin (Invokana). [2] Prior authorization approvals typically run for 12 months and require re-authorization annually.

For the heart failure indication, the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure gives empagliflozin a Class I, Level of Evidence A recommendation for patients with heart failure with reduced ejection fraction, and a Class IIa recommendation for preserved ejection fraction. [3] Virginia Medicaid generally aligns coverage decisions with these class-level guideline designations, which strengthens the PA approval rate for heart failure patients.

For CKD, the EMPA-KIDNEY trial (N=6,609) showed empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% relative to placebo over a median follow-up of 2 years. [4] Virginia Medicaid accepts EMPA-KIDNEY data as clinical support in PA submissions.

Dual-eligible patients (Medicare-Medicaid) in Virginia typically have Jardiance covered under the Medicare Part D benefit. Medicaid then acts as a secondary payer for cost-sharing, potentially reducing the patient's out-of-pocket to $0 under the Low Income Subsidy.

How the Boehringer Ingelheim and Lilly Savings Card Works in Virginia

Commercially insured Virginia patients who are not enrolled in any federal or state government health program can use the Boehringer Ingelheim and Eli Lilly co-pay savings card to pay as little as $10 per month for Jardiance. The card is accepted at retail pharmacies statewide including Rite Aid, Giant Food pharmacies, and independent chains throughout the Shenandoah Valley and Southwest Virginia.

The card covers up to $150 per fill, which means it typically absorbs the full commercial plan co-pay for most Virginia employer-sponsored insurance tiers. Patients activate the card online or by phone, and most Virginia pharmacies process it in real time at the point of sale.

Eligibility rules are strict. The savings card is explicitly not available to patients whose prescriptions are paid for by Medicaid, Medicare, TRICARE, or any other state or federal assistance program. Virginia federal employees enrolled in the Federal Employees Health Benefits (FEHB) program are generally eligible for the commercial savings card, though individual plan rules vary.

The manufacturer savings program does not cap annual benefit in a defined way but adjusts based on the contracted rate between the pharmacy and the benefit manager. Virginia patients with high-deductible health plans often see the most value from the card during the deductible accumulation phase in Q1 of each plan year.

Which Virginia Insurance Plans Cover Jardiance?

Most commercial insurance plans operating in Virginia cover Jardiance, though tier placement and required steps vary substantially. [5]

Anthem BCBS Virginia. Anthem places Jardiance on Tier 3 (preferred brand) for most employer-sponsored plans. A prior authorization is required for the heart failure and CKD indications; the diabetes indication typically requires only a step-therapy through metformin documentation. Co-pays for Tier 3 drugs under standard Anthem Virginia plans run $50 to $90 per 30-day supply before deductible.

Cigna / Evernorth Virginia. Cigna's commercial formularies in Virginia list empagliflozin as Tier 3 with step therapy. Patients who have tried and failed or cannot tolerate metformin can satisfy step therapy with a letter of medical necessity.

Aetna CVS Virginia. Aetna places Jardiance on Tier 3 or Tier 4 depending on the specific employer plan document. The CVS Caremark pharmacy benefit manager processes Jardiance claims and applies the manufacturer co-pay card automatically at in-network CVS locations.

UnitedHealthcare Virginia. UHC commercial plans in Virginia generally list Jardiance at Tier 3 with a quantity limit of 30 tablets per 30 days and prior authorization for non-diabetes indications.

Virginia state employee plans (COVA Care, COVA HealthAware). The Commonwealth of Virginia health plans administered through Optima Health and Aetna cover Jardiance at Tier 3 with PA for non-diabetes indications. State employees pay approximately $60 to $80 per 30-day fill after meeting the annual deductible.

For Medicare Part D enrollees, plan formularies change annually. The 2026 Medicare Part D out-of-pocket cap of $2,000 (established by the Inflation Reduction Act) applies, meaning Virginia Medicare beneficiaries who need Jardiance long-term will pay no more than $2,000 total out-of-pocket for all Part D drugs in a calendar year. [6]

Is Compounded Empagliflozin Legal in Virginia?

Compounded empagliflozin is legal in Virginia through state-licensed 503A compounding pharmacies. The distinction matters. A 503A pharmacy compounds medication for an individual patient upon receipt of a valid, patient-specific prescription from a licensed Virginia prescriber. These pharmacies are regulated by the Virginia Board of Pharmacy under Virginia Code section 54.1-3410.1.

The FDA regulates compounded drugs differently from commercially approved products. Compounded empagliflozin is not FDA-approved and has not passed the agency's bioequivalence review process. [7] That does not make it illegal; it means the compounded version is prepared under pharmacy practice law rather than drug approval law.

Virginia Board of Pharmacy rules require that 503A compounders use pharmaceutical-grade active pharmaceutical ingredients (API) sourced from FDA-registered facilities. Empagliflozin API is commercially available from such facilities, so Virginia 503A pharmacies can legally compound it in capsule or tablet form. The prescriber must document a clinical rationale for why the compounded preparation serves the individual patient's needs.

Pricing through 503A pharmacies varies. Some Virginia telehealth providers partnered with compounding pharmacies offer empagliflozin at $0 per month under subscription or membership models, absorbing the cost of the medication into a monthly platform fee. Cash pricing at independent 503A compounders in Virginia typically falls in the range of $30 to $80 per month for a 10 mg daily capsule, a steep discount from the $680 brand list price.

Patients should verify that any 503A pharmacy they use holds an active license with the Virginia Board of Pharmacy. The board's license lookup tool is publicly available at dhp.virginia.gov. Compounded empagliflozin should not be confused with 503B outsourcing facility products, which are intended for hospital and clinic bulk use and are generally not dispensed directly to patients.

The Clinical Evidence Behind Empagliflozin

Understanding why providers and insurers take empagliflozin seriously helps explain the push to access it regardless of cost barriers.

EMPA-REG OUTCOME (N=7,020) published in the New England Journal of Medicine in 2015 showed that empagliflozin 10 mg or 25 mg added to standard care reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% relative to placebo (HR 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority) in patients with type 2 diabetes and established cardiovascular disease. [8] Cardiovascular death alone fell by 38%.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% versus placebo in patients with heart failure with reduced ejection fraction, regardless of diabetes status. [9] The EMPEROR-Preserved trial (N=5,988) extended this benefit to patients with preserved ejection fraction, making empagliflozin the first SGLT2 inhibitor to show benefit across the full ejection fraction spectrum. [10]

The ADA Standards of Medical Care in Diabetes 2024 state: "In patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events." [11] Empagliflozin's EMPA-REG data are the most cited evidence supporting that recommendation.

For weight-related metabolic benefit, empagliflozin produces a mean body weight reduction of approximately 2 to 3 kg versus placebo in 24-week trials, a more modest effect than GLP-1 receptor agonists but clinically meaningful for patients who cannot tolerate GLP-1 agents. [12] HbA1c reductions average 0.5% to 0.8% from baseline at standard doses. [13]

Virginia clinicians prescribing empagliflozin for any off-label indication, such as obesity without diabetes, should be aware that Virginia Medicaid and most commercial plans require an approved indication to authorize coverage. Off-label compounded use does not trigger the same restrictions at 503A pharmacies, provided the prescriber documents individualized medical need.

Can You Get a Jardiance Prescription Via Telehealth in Virginia?

Yes. Virginia law permits telehealth prescribing of controlled and non-controlled medications, including Jardiance, when a valid patient-provider relationship is established. Empagliflozin is not a controlled substance, so the federal Ryan Haight Act requirements that govern telehealth prescribing of Schedule II to V drugs do not apply. [14]

Virginia passed the Virginia Telehealth Initiative under the Code of Virginia section 38.2-3418.16, requiring commercial insurers to reimburse telehealth services at parity with in-person visits. [15] This means a Virginia telehealth visit to establish care and receive an empagliflozin prescription carries the same coverage terms as an endocrinology or primary care office visit under most commercial plans.

Telehealth providers operating in Virginia must hold an active Virginia medical license or prescriber license. Out-of-state providers cannot prescribe to Virginia patients unless they hold Virginia licensure or qualify under the Interstate Medical Licensure Compact (IMLC), in which Virginia participates.

For patients seeking compounded empagliflozin through a Virginia telehealth platform, the workflow is straightforward: complete an asynchronous or synchronous visit, receive a prescription, and have it sent to a Virginia-licensed 503A compounding pharmacy. Some platforms expedite this process to same-day or next-day dispensing.

Virginia-Specific Discount Programs and Patient Assistance

Beyond the manufacturer savings card, Virginia patients have several additional pathways to reduce empagliflozin costs.

NeedyMeds. The NeedyMeds database lists Jardiance under the Boehringer Ingelheim Cares Foundation patient assistance program. Virginia residents with income at or below 400% of the federal poverty level and no other prescription coverage may receive Jardiance at no cost by applying through the manufacturer. [16]

RxAssist. RxAssist aggregates manufacturer patient assistance programs and includes detailed application instructions for Virginia. The application requires a prescriber's signature and documentation of income and insurance status.

Virginia Health Benefit Exchange (VHBE). Virginia residents who purchase insurance through the state marketplace may qualify for cost-sharing reductions that lower Jardiance co-pays to $20 to $40 per fill for Silver-tier plans.

Virginia 340B Program. Federally qualified health centers (FQHCs) and qualifying rural health clinics in Virginia participate in the 340B drug pricing program. Patients receiving care at these facilities may access Jardiance at the 340B ceiling price, which is substantially below the retail list price. Clinics in rural Southwest Virginia, the Eastern Shore, and parts of Northern Neck serve populations with elevated cardiovascular and diabetes risk who could benefit most from 340B pricing.

The HealthRX Virginia Empagliflozin Access Framework ranks the pathways above by expected monthly cost for a typical patient:

| Pathway | Estimated Monthly Cost (Virginia, 2026) | |---|---| | Compounded 503A (via telehealth, membership model) | $0 to $30 | | 340B FQHC | $5 to $20 | | Manufacturer patient assistance | $0 | | Commercial plan + BI/Lilly savings card | $10 | | Virginia Medicaid (post-PA approval) | $0 to $3.90 co-pay | | Commercial plan (Tier 3, no savings card) | $50 to $90 | | GoodRx cash price | $560 to $630 | | Retail cash, no discount | ~$680 |

How to Start Empagliflozin Safely in Virginia

Starting empagliflozin requires a prescription from a licensed Virginia prescriber. Before writing the prescription, the clinician should confirm eGFR because empagliflozin's glucose-lowering efficacy diminishes at eGFR <30 mL/min/1.73 m2, though the cardiovascular and renal protective effects persist at lower eGFR values per EMPA-KIDNEY data. [4]

The standard starting dose is 10 mg once daily in the morning, with or without food. The dose may be increased to 25 mg daily for additional glucose lowering if tolerated. For heart failure and CKD indications, 10 mg once daily is the only studied and approved dose. [1]

Patients should be counseled on the signs of diabetic ketoacidosis (DKA), a rare but serious adverse event reported at a rate of approximately 0.1% in clinical trials, and on genital mycotic infections, which occur in roughly 6% of women and 3% of men. [8] Holding empagliflozin at least 3 to 4 days before elective surgery or prolonged fasting reduces DKA risk, per ADA perioperative guidance.

Virginia prescribers who identify a patient for the 503A compounded pathway should include the specific dose, strength, and dosage form on the prescription, along with a brief clinical note indicating why the compounded preparation meets the individual patient's needs. This documentation protects the prescriber and the pharmacy during any Board of Pharmacy review.